CEO/CSO, 10% Owner of Progenics Pharmaceuticals Inc. (PGNX, Financial) Paul J Maddon buys 18,500 shares of PGNX on 10/16/2009 at an average price of $4.88 a share.
Progenics Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development & commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company in collaboration with Wyeth is developing methylnaltrexone for the treatment of opioid-induced side effects including constipation and post-operative ileus. In the area of HIV infection the Company is developing the viral-entry inhibitor PRO one hundred forty a humanized monoclonal antibody targeting the HIV coreceptor CCR5. In addition the Company is conducting research on ProVax a novel prophylactic HIV vaccine. Progenics Pharmaceuticals Inc. has a market cap of $154.54 million; its shares were traded at around $5.03 with and P/S ratio of 2.28.
Progenics Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development & commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company in collaboration with Wyeth is developing methylnaltrexone for the treatment of opioid-induced side effects including constipation and post-operative ileus. In the area of HIV infection the Company is developing the viral-entry inhibitor PRO one hundred forty a humanized monoclonal antibody targeting the HIV coreceptor CCR5. In addition the Company is conducting research on ProVax a novel prophylactic HIV vaccine. Progenics Pharmaceuticals Inc. has a market cap of $154.54 million; its shares were traded at around $5.03 with and P/S ratio of 2.28.
Insiders' Positions with PGNX
- Sell:: CFO on 06/19/2009 Robert A Mckinney sold 5,000 shares of PGNX stock at the average price of 5.25, the price of the stock has decreased by 4.19% since
Insiders' Positions with PGNX
- Sell:: VP, Research & Development on 06/23/2009 William C Olson sold 2,500 shares of PGNX stock at the average price of 4.73, the price of the stock has increased by 6.34% since
- Sell:: Sr. VP, Product Dev. on 06/23/2009 Thomas A Boyd sold 2,000 shares of PGNX stock at the average price of 4.73, the price of the stock has increased by 6.34% since
